Announcements Trials
Browse Landscape

Clinical Trials

1 trials
RecentStart dateEnrollment
PFS × Clear all

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 13011Neoplasms 10392Carcinoma, Non-Small-Cell Lung 6808Prostatic Neoplasms 6205Colorectal Neoplasms 5873Lung Neoplasms 5047Multiple Myeloma 3545Pancreatic Neoplasms 3516Neoplasm Metastasis 3482Leukemia, Myeloid, Acute 3471Carcinoma, Hepatocellular 3235Ovarian Neoplasms 3144Melanoma 3120Stomach Neoplasms 3024Lymphoma 2971Head and Neck Neoplasms 2576Recurrence 2532Precursor Cell Lymphoblastic Leukemia-Lymphoma 2486Leukemia 2354Colonic Neoplasms 2320Brain Neoplasms 2296Lymphoma, Non-Hodgkin 2259Rectal Neoplasms 2174Uterine Cervical Neoplasms 2168Glioblastoma 1997Leukemia, Lymphocytic, Chronic, B-Cell 1985Carcinoma, Renal Cell 1898Squamous Cell Carcinoma of Head and Neck 1859Lymphoma, Follicular 1831Esophageal Neoplasms 1785

Interventions

Bevacizumab 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT05267288 2023-03-29

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Qingdao Central Hospital

Phase 2 Unknown
30 enrolled

PFS

Data powered by HemOnc (CC BY 4.0) Colophon âš¡